Clinical epigenetics: seizing opportunities for translation.
Citations
4,409 citations
240 citations
Cites background from "Clinical epigenetics: seizing oppor..."
...The potential of epigenetic drugs is extending to other pathologies, from infectious diseases to brain diseases, cardiovascular and metabolic disorders [5, 116]....
[...]
...Their use is restricted to CTCL and PTCL patients when other treatment options have failed [5]....
[...]
138 citations
Cites background from "Clinical epigenetics: seizing oppor..."
...One of the best-characterized epigenetic markers is the hypermethylation of the glutathione S-transferase (GSTP1) gene in the biological fluids of prostate cancer patients [42, 44, 45]....
[...]
...Although at present only two classes of epigenetic drugs have been approved by the US Food and Drug Administration (FDA)—DNA methylation inhibitors (iDNMTs) and histone deacetylase inhibitors (iHDACs)—several new targets are in late-stage clinical trials and show therapeutic promise [31, 42, 47, 66] (Fig....
[...]
...Epigenetic biomarkers can be useful to predict therapeutic drug response [42, 44, 45]....
[...]
118 citations
Cites background from "Clinical epigenetics: seizing oppor..."
...DNA methylation modifications are highly stable compared to RNA- or proteinbased biomarkers, relatively easy to measure using non-invasive biospecimen, and are quantifiable marks on the DNA that can track the influences of various environmental and lifestyle factors (Berdasco and Esteller, 2019)....
[...]
113 citations
References
7,797 citations
6,018 citations
5,037 citations
4,409 citations
4,016 citations